BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 6687694)

  • 1. [Acute leukemias and solid tumors in the course of Hodgkin disease].
    Jacquillat C; Auclerc G; Weil M; Auclerc MF; Maral J
    Bull Cancer; 1983; 70(1):61-6. PubMed ID: 6687694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the risk of solid tumor following Hodgkin's disease.
    Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C
    Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic chemotherapy-induced second primary neoplasms: clinical aspects.
    Petru E; Schmähl D
    Neoplasma; 1991; 38(2):147-55. PubMed ID: 2041574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
    Valagussa P; Bonadonna G
    Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
    [No Abstract]   [Full Text] [Related]  

  • 7. Second malignancy complicating Hodgkin's disease.
    Tawil E; Mercier JP
    J Can Assoc Radiol; 1983 Jun; 34(2):108-13. PubMed ID: 6688422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin's disease, splenectomy and secondary leukemia.
    Centurioni R; Brianzoni F; Leoni P; Danieli G
    Haematologica; 1993; 78(4):258-9. PubMed ID: 8294062
    [No Abstract]   [Full Text] [Related]  

  • 9. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of Hodgkin's disease. Experience of the Hôpital Saint-Louis].
    Boiron M; Teillet F; Weisgerber C; Dana M; Jacquillat C; Bernard J
    Rev Prat; 1974 Oct; 24(45):3971-8. PubMed ID: 4445767
    [No Abstract]   [Full Text] [Related]  

  • 11. [Acute leukemia in patients treated for Hodgkin's disease].
    Boccaccio P; Rosa F; Casciaro S; D'Elia P; Romagnoli M; Ghio R
    Recenti Prog Med; 1988 Jan; 79(1):32-7. PubMed ID: 3375542
    [No Abstract]   [Full Text] [Related]  

  • 12. [Secondary malignant tumors following treatment of Hodgkin's disease].
    Shishkin IP
    Med Radiol (Mosk); 1984 Aug; 29(8):24-8. PubMed ID: 6590941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin's disease.
    Henry-Amar M
    J Natl Cancer Inst; 1983 Nov; 71(5):911-6. PubMed ID: 6580491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Second tumors in patients treated for Hodgkin's disease].
    España P; Bonilla F; Yebra M; Diego J; Alvarez de Mon M; Marazuela M; Durántez A
    Rev Clin Esp; 1988 Apr; 182(6):304-6. PubMed ID: 3406475
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cured from Hodgkin's disease].
    Brice P
    Bull Cancer; 2002; 89(7-8):666-70. PubMed ID: 12206979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Second tumor following Hodgkin's disease].
    Schmitt K; Tulzer W
    Padiatr Padol; 1984; 19(3):259-62. PubMed ID: 6548008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
    Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P
    Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.